Mushrooms and Influenza: What the Research Actually Shows

Beta-Glucans

4 genera

A 2021 review dedicated specifically to medicinal mushrooms and influenza identified four mushroom genera with documented anti-influenza activity (Ganoderma, Lentinus, Trametes, and Inonotus) spanning direct viral inhibition and immune activation.

Teplyakova et al., International Journal of Medicinal Mushrooms, 2021

H1N1 inhibition

demonstrated in cell culture by multiple Basidiomycete species, some reaching potency of antiviral reference compounds

Hemagglutinin

the flu virus attachment protein physically blocked by ganoderic acids and sulfated polysaccharides in reishi

2 mechanisms

direct antiviral activity vs. immune activation, each requiring a different timing strategy to be effective

Teplyakova et al., International Journal of Medicinal Mushrooms, 2021

View as image ↗

Influenza kills between 290,000 and 650,000 people every year. That wide range reflects how dramatically outcomes shift when a new strain circulates. Our main defenses are vaccines, which require annual reformulation because the virus mutates, and antivirals like oseltamivir, which reduce illness duration by roughly one day when taken within 48 hours of the first symptom. Neither is a clean solution.

Researchers have studied whether medicinal mushrooms offer a third option. Not a treatment, but immune preparation. The literature on mushrooms and influenza spans two meaningfully different categories: direct antiviral activity, where mushroom compounds physically interfere with viral replication; and immune activation, where mushrooms prime the body's natural defenses before exposure. These categories require different timing of supplementation and produce different benefits. The distinction between them is almost entirely absent from consumer content on this topic.

A note on foundation: many of the mechanisms described here operate through beta-glucans, the polysaccharide compounds responsible for much of the immune activity in medicinal mushrooms. For a complete explanation of how beta-glucans work, see what beta-glucans are and why they matter.

The Four Mushroom Genera With Anti-Influenza Evidence

A 2021 review by Teplyakova and colleagues in the International Journal of Medicinal Mushrooms focused specifically on anti-influenza evidence across mushroom species.^[1] Four genera emerged with the strongest support: Ganoderma (reishi), Lentinus (shiitake), Trametes (turkey tail), and Inonotus (which includes chaga and related bracket fungi). An earlier broad review by the same research group found similar patterns across these species in the context of a wider range of viruses, including influenza A.^[4]

The genus Ganoderma has the most mechanistic data on influenza specifically. Reishi contains ganoderic acids (triterpene compounds found in this genus) and sulfated polysaccharides, both of which appear to interfere with influenza's initial step of infection.^[1]

Trametes versicolor (turkey tail) is notable in this group because the polypore class, which includes turkey tail and related bracket fungi, is also the subject of a 2026 human randomized controlled trial on vaccine immune response. That study tested polypore mushroom mycelium supplementation alongside COVID-19 vaccination to measure whether it improved antibody responses. For a full discussion of that trial, see mushrooms and antiviral defense: from influenza to SARS-CoV-2.

Inonotus species, including chaga, appear consistently across antiviral mushroom literature for several viruses. The 2016 Teplyakova review of Agaricomycetes as a class documents antiviral activity across Ganoderma, Lentinus, Trametes, and Inonotus, establishing that anti-influenza properties are not specific to one unusual genus but are distributed across the most well-studied medicinal mushroom families.^[4]

How Mushroom Compounds Attack Influenza at the Cellular Level

The way influenza infects a cell is well understood. The virus uses a surface protein called hemagglutinin, the "H" in H1N1, to grab onto sialic acid docking sites on the surface of your respiratory cells. Once it attaches, it enters the cell and begins replicating.

Several mushroom compounds appear to physically interfere with this attachment step. According to the 2021 Teplyakova review, ganoderic acids and polysaccharides from Ganoderma and related genera can block hemagglutinin from reaching sialic acid receptors on the cell surface.^[1] Without that initial lock-and-key binding, the virus cannot enter the cell.

This is a direct antiviral mechanism. It does not rely on the immune system. It works through a similar principle to antiviral drugs, which also target specific steps in the viral infection process, though at a different molecular target. Oseltamivir (Tamiflu) inhibits neuraminidase, the "N" protein, which allows newly assembled viral particles to escape from an infected cell. Mushroom compounds appear to target the upstream attachment step instead.

Sulfated polysaccharides, a structural variant of normal mushroom polysaccharides with extra negatively charged groups attached, showed particularly strong activity in the hemagglutinin-blocking studies.^[1] The sulfate groups may mimic the negative charge of sialic acid receptors, effectively distracting hemagglutinin away from the actual cell surface. That is a structural explanation for why the chemical form of the polysaccharide matters, not just the dose.

Ergosterol, the precursor to vitamin D found in mushroom cell walls, is also noted in the 2021 review as contributing to anti-influenza activity, though through less precisely characterized mechanisms than the hemagglutinin-blocking compounds.^[1]

Cell Culture Data: How Specific Species Ranked Against H1N1

Reviews identify which species have evidence; cell culture studies provide the actual inhibition numbers. In 2014, Krupodorova and colleagues tested multiple Basidiomycete species against both H1N1 influenza and herpes simplex virus type 2 in cell culture, ranking each species by antiviral potency.^[2] The strongest performers reached activity levels comparable to the antiviral reference compounds used as positive controls in the experiment. Not all tested species showed significant activity, but several stood out as particularly potent against H1N1.

In 2012, a separate study by Teplyakova screened polyporoid mushrooms specifically, gathered from the Altai Mountains region of Russia, for anti-influenza and anti-herpes activity.^[5] Several species showed anti-influenza activity, adding geographic and species diversity to the picture. This matters because polypore mushrooms (bracket fungi like turkey tail, chaga, and reishi) consistently produce antiviral results across different research groups, species sources, and extraction conditions.

Two important caveats apply to all cell culture work. First, these studies measure what happens to viruses in a laboratory dish, not in a living person where viruses face immune defenses, stomach acid, metabolic processing, and distribution to target tissues. Second, the concentrations of mushroom compounds used in cell culture may not be achievable through oral supplementation. Cell culture data establishes that mushroom compounds have antiviral properties at the molecular level. It does not establish effective doses or outcomes in humans.

The Shiitake Surprise: Different Beta-Glucan Fractions Produce Different Immune Effects

Here is something almost entirely absent from consumer mushroom content: beta-glucans from the same mushroom do not all do the same thing. The compound class is not monolithic.

In 2020, Murphy and colleagues published research in Science of the Total Environment examining what happens when you separate shiitake beta-glucans into distinct fractions based on particle size, molecular weight, and structural characteristics.^[3] The fractions produced strikingly different immune responses in cell culture.

Some fractions strongly stimulated NK cell activity. NK cells (natural killer cells) are part of the innate immune system. Their job is to recognize and destroy cells that have already been infected by a virus, before that infected cell can produce more viral copies. Enhanced NK cell activity means faster clearance of influenza-infected tissue before the virus can spread further through respiratory epithelium.

Other fractions provided pulmonary cytoprotection. In plain terms: they protected lung cells from damage. Murphy et al. explicitly noted the COVID-19 relevance in their title, but the mechanism is equally relevant to influenza, which causes respiratory damage in severe cases through both direct viral destruction of lung tissue and inflammatory injury.

The key finding: the specific fraction or extraction method used to produce a beta-glucan product determines what type of immune support it generates. A hot water extract that preserves the triple-helix molecular structure of beta-glucans may activate NK cells more effectively than an alcohol extract that disrupts that structure. A product standardized to beta-glucan percentage by weight may contain very different structural forms depending on the extraction process.

This is also why a beta-glucan percentage on a supplement label is not the complete picture. For a deeper breakdown of how beta-glucan structure affects function, see mushroom beta-glucans and viral immune response. And for how beta-glucans trigger long-term changes in how immune cells respond to future threats, see how beta-glucans epigenetically reprogram immune cells.

Why Taking Mushrooms After You're Already Sick Is Probably the Wrong Strategy

The direct antiviral mechanism and the immune activation mechanism operate on completely different timescales. Confusing them leads to unrealistic expectations.

Direct antiviral activity, such as blocking hemagglutinin binding, requires that mushroom compounds be present at the site of infection when the virus arrives. Theoretically, continuous supplementation could maintain relevant concentrations in respiratory mucosa. In practice, the pharmacokinetics of mushroom polysaccharides in humans are not well characterized, and it is not established that oral supplementation produces mucosal concentrations sufficient for direct antiviral effects.

Immune activation through beta-glucans works through a different process and a different timeline. Beta-glucans bind to dectin-1 receptors on immune cells and trigger what researchers call trained immunity: a persistent state of heightened antiviral readiness in macrophages and monocytes. The immune cells have been, in a sense, pre-trained to respond faster and more vigorously when viral signals appear. This process takes weeks to develop and requires consistent supplementation before viral exposure, not acute dosing once symptoms begin.

Taking mushroom supplements when flu symptoms appear is working through the wrong mechanism at the wrong time. The trained immunity effects require prior establishment. The direct antiviral effects at achievable oral doses in humans remain unproven. This is the opposite of how oseltamivir works, and mushroom supplements should not be framed as a flu treatment equivalent.

For the annual flu season, the more evidence-consistent strategy is sustained supplementation starting well before exposure, aiming to establish the trained immunity and NK cell priming that beta-glucan research describes. This is immune preparation, not rescue. These are different things.

The Honest Limitations: No Human Flu Trials Exist

There are no randomized controlled trials testing mushroom supplementation against influenza in humans. The entire anti-influenza evidence base for medicinal mushrooms comes from cell culture studies and review papers that synthesize that laboratory data.

The closest human evidence is from adjacent research. The 2026 Saxe et al. randomized controlled trial published in BMC Immunology tested polypore mushroom mycelium supplementation alongside COVID-19 vaccination, measuring whether it improved antibody responses to the vaccine. This is the most rigorous human evidence connecting mushrooms to antiviral immune function. It tests whether polypore mushrooms, the same class that includes turkey tail and chaga, can meaningfully enhance a vaccine-driven antibody response in real people. COVID-19 vaccines and influenza vaccines use mechanistically similar immune processes. The COVID-19 vaccine trial does not directly answer the influenza question, but it is the most controlled human proxy available for mushroom effects on antiviral immune response.

The rest of the human clinical evidence for mushroom antiviral effects comes from non-influenza contexts: hepatitis B liver function normalization from Agaricus blazei extract (Hsu et al., 2008), and CD4+ T-lymphocyte increases in HIV patients from a mushroom blend study (Adotey et al., 2011). Neither directly addresses influenza.

What the research does support: multiple medicinal mushroom species demonstrate anti-influenza H1N1 activity in controlled laboratory settings, through mechanisms that are pharmacologically coherent. What the research does not support: clinical conclusions about efficacy against influenza in human patients, or specific dosing recommendations for flu prevention.

This is not a reason to dismiss the research. It is an accurate description of where the science currently stands.

Which Mushroom Species Have the Strongest Influenza Evidence?

Based on the published laboratory and review literature:

Ganoderma lucidum (Reishi): Has the most specific mechanistic data for influenza. Ganoderic acids and sulfated polysaccharides blocking hemagglutinin binding make reishi the best-characterized anti-influenza mushroom at the molecular level.^[1]

Lentinus edodes (Shiitake): Beta-glucan fractions with both NK cell activation and pulmonary cytoprotection. Lentinan, shiitake's primary beta-glucan, is one of the most studied mushroom immune compounds, with decades of clinical use history in Japan for immune support.^[3]

Trametes versicolor (Turkey Tail): Consistent antiviral activity across multiple Teplyakova studies; as a polypore, it belongs to the same class used in the 2026 COVID vaccine adjuvant trial, providing the most relevant human clinical context.^[4]

Inonotus obliquus (Chaga): Documented anti-influenza activity in multiple reviews, with polyphenolic compounds that show activity against both influenza and herpes viruses. The Altai Mountain polypore screening study provides species-level data for related Inonotus relatives.^[5]

For the broader landscape of antiviral mushroom compounds beyond polysaccharides, including lectins and terpenoids that also show anti-influenza and anti-herpes activity, see medicinal mushrooms as antivirals: what the research shows.

The Bottom Line

Several medicinal mushroom species, particularly Ganoderma, Lentinus, Trametes, and Inonotus, have demonstrated anti-influenza H1N1 activity in controlled cell culture studies through mechanisms including hemagglutinin binding inhibition and NK cell activation. Different beta-glucan fractions from the same mushroom can produce meaningfully different immune effects, from NK cell stimulation to lung cell protection. No human clinical trials have tested mushrooms specifically against influenza; the strongest human proxy evidence comes from a 2026 RCT on polypore mushroom mycelium as a COVID vaccine adjuvant. The evidence is preclinical but pharmacologically coherent.

Frequently Asked Questions

Can mushrooms prevent the flu?

No human trials have tested whether mushrooms prevent influenza, so a definitive answer isn't possible. Lab studies show that compounds from several mushroom species block H1N1 replication and block hemagglutinin binding at the cellular level, and beta-glucan supplementation is documented to prime NK cells and macrophages into a state of heightened antiviral readiness (trained immunity). These mechanisms are biologically relevant to influenza prevention, but clinical evidence in people does not yet exist for flu specifically.

Do mushrooms help with influenza?

Cell culture studies demonstrate that multiple medicinal mushroom species inhibit influenza H1N1 replication, with some species reaching potency comparable to antiviral reference compounds in controlled conditions. Mechanisms include blocking hemagglutinin attachment to host cells and stimulating NK cell and interferon responses. There are no human clinical trials on mushrooms and influenza; the available evidence is laboratory-based, with a 2026 randomized trial on polypore mushrooms and COVID vaccine antibody response providing the closest human proxy.

Which mushroom is best for flu prevention?

Ganoderma lucidum (reishi) has the most specific mechanistic data for influenza, with ganoderic acids and sulfated polysaccharides that block hemagglutinin binding. Trametes versicolor (turkey tail) belongs to the polypore class tested in the 2026 COVID vaccine adjuvant RCT, giving it the strongest human clinical context. Lentinus edodes (shiitake) provides both NK cell activation and pulmonary cytoprotection through different beta-glucan fractions. Chaga (Inonotus obliquus) shows consistent anti-influenza activity across multiple screening studies.

Can mushrooms shorten flu duration?

No human studies have tested whether mushrooms reduce influenza duration. Oseltamivir (Tamiflu), the standard antiviral, reduces illness duration by approximately one day when taken within 48 hours of symptoms appearing. Mushroom compounds have not been tested in this post-symptom, acute-treatment context in humans. The immune activation mechanisms from beta-glucan supplementation require weeks of prior use to be in place, and are not suited to an acute treatment model.

Are mushrooms as effective as flu vaccines?

Flu vaccines and mushrooms act through different mechanisms and are not comparable as alternatives. Vaccines stimulate strain-specific antibody production against the viruses forecast to circulate that season. Mushrooms appear to enhance general innate immune readiness through trained immunity, NK cell priming, and interferon induction. The 2026 Saxe RCT investigated whether polypore mushrooms could improve COVID vaccine antibody responses when taken alongside vaccination, not instead of vaccination. These mechanisms may be complementary, not substitutes.

Sources & References

1. 1RTHM-00723·Teplyakova, Tamara V et al. (2021). “Medicinal Mushrooms against Influenza Viruses..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
2. 2RTHM-00331·Krupodorova, Tetiana et al. (2014). “Antiviral activity of Basidiomycete mycelia against influenza type A (serotype H1N1) and herpes simplex virus type 2 in cell culture..” Virologica Sinica.Study breakdown →PubMed →↩
3. 3RTHM-00638·Murphy, Emma J et al. (2020). “β-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies..” The Science of the total environment.Study breakdown →PubMed →↩
4. 4RTHM-00450·Teplyakova, Tamara V et al. (2016). “Antiviral Effect of Agaricomycetes Mushrooms (Review)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
5. 5RTHM-00265·Teplyakova, Tamara V et al. (2012). “Antiviral activity of polyporoid mushrooms (higher Basidiomycetes) from Altai Mountains (Russia)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩